STAYVEER (bosentan): Reviews and patient testimonials
Back to the list of medications
Medication indications
STAYVEER 62.5 mg & 125 mg film-coated tablets
Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:
• Primary (idiopathic and heritable) pulmonary arterial hypertension
• Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease
• Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology
Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II.
STAYVEER is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
Route of administration: Oral
Molecule: bosentan
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.